Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome.
Multivariate analysis was used to identify which of a large number of pretreatment immunological parameters correlated with therapeutic response, subsequent development of opportunistic infection, and survival from the time of diagnosis in a group of 70 patients with Kaposi's sarcoma and acquired immunodeficiency syndrome treated with recombinant leukocyte A interferon. In a logistic regression model, delayed type hypersensitivity response to one or more recall antigens and high proliferative response to Escherichia coli were significant predictors for response to recombinant leukocyte A interferon (for the model, P = 0.01). For prediction of the development of opportunistic infection, the model selected low proliferative responses to phytohemagglutinin and E. coli (P less than 0.001). Favorable factors predicting survival in the Cox regression model were the absence of endogenous serum interferon activity and a high proliferative response to E. coli (P less than 0.001). The estimated median survival for the group with endogenous serum interferon activity and low E. coli response was 12 months; the median has not yet been reached for the group with no serum interferon and a high E. coli response. We conclude that immunological parameters may be useful in predicting prognosis in patients with Kaposi's sarcoma and acquired immunodeficiency syndrome.
S
S
Vadhan-Raj
G
G
Wong
C
C
Gnecco
S
S
Cunningham-Rundles
M
M
Krim
F X
FX
Real
H F
HF
Oettgen
S E
SE
Krown
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000628:therapy; D000945:Antigens, Differentiation, T-Lymphocyte; D000954:Antigens, Surface / Q000032:analysis; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007136:Immunoglobulins / Q000032:analysis; D007370:Interferon Type I / Q000627:therapeutic use; D007372:Interferons / Q000097:blood; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation; D011379:Prognosis; D011994:Recombinant Proteins / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000276:immunology* / Q000628:therapy; D012882:Skin Tests; D013601:T-Lymphocytes / Q000145:classification; D013997:Time Factors; D001613:beta 2-Microglobulin / Q000032:analysis
D000945:Antigens, Differentiation, T-Lymphocyte; D000954:Antigens, Surface; D007136:Immunoglobulins; D007370:Interferon Type I; D011994:Recombinant Proteins; D001613:beta 2-Microglobulin; D007372:Interferons